GSK-205687

Study Sponsor: GSK

Study Title

A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps - SYNAPSE (StudY in NAsal Polyps patients to assess the Safety and Efficacy of mepolizumab)

Medicine or Vaccine (generic name)

mepolizumab

Sponsor Identification Number

205687

Trial Registry Identification Number(#'s)

NCT03085797 2016-004255-70

Medical Condition

Polyps, Nasal

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205687

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03085797

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-004255-70

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

May 2021